Dorman Products Reports Q4 Loss on Goodwill Impairment, Projects Lower 2026 Adjusted EPS
DORM is trading near its 52-week low of $106.95 (6.9% above the low) on elevated volume (2.9× avg).
Summary
Dorman Products announced Q4 2025 results, including a $51.1 million goodwill impairment, and issued 2026 guidance projecting lower adjusted EPS despite sales growth.
Key Events · Earnings and Guidance · DORM
-
Significant Goodwill Impairment
The company recorded a $51.1 million non-cash goodwill impairment charge related to its Heavy Duty segment in Q4 2025, causing GAAP diluted EPS to drop 79% to $0.38 for the quarter.
-
Full Year 2025 Performance
For the full year 2025, net sales increased by 6.0% to $2.13 billion, and adjusted diluted EPS grew by 24% to $8.87, despite the Q4 impairment.
-
Mixed 2026 Guidance Issued
Dorman Products expects 2026 net sales to grow 7% to 9% year-over-year, but projects adjusted diluted EPS to decline by 9% to 4% to a range of $8.10 to $8.50, signaling potential margin pressure.
Analysis · DORM · Manufacturing
Dorman Products reported a significant non-cash goodwill impairment charge of $51.1 million in the fourth quarter of 2025, which led to a 79% decline in GAAP diluted EPS for the quarter. While full-year 2025 adjusted diluted EPS grew by 24%, the company's 2026 guidance projects a 9% to 4% decline in adjusted diluted EPS, despite an expected 7% to 9% increase in net sales. This indicates anticipated margin compression or increased operational costs, which could concern investors focused on profitability.
At the time of this filing, DORM was trading at $114.30 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $106.95 to $166.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.